Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding
NCT06870344Active, not recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of dihydroartemisinin + piperaquine in malaria (3 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Cluster-level Incidence of malaria in children <= 12 years of age at 12 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06870344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06870344.